| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – |
| 29 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 202... |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – |
| 03 Jun 2026 |
8-K: Other Events
Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Goldman Sachs & Co. LLC (“GS”) and Evercore Group L.L.C. (“Evercore”) (collectively, the “Underwriters,” wh... |
| 03 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On June 2, 2026, Mineralys Therapeutics, Inc. (the “Company”) entered into a fourth amendment (the “Amendment”) to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025 (the “... |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, Mineralys Therapeutics, Inc. (the Company) held its 2026 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown: |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results |
| 06 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – |
| 03 Sep 2025 |
8-K: Other Events
Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Evercore Group L.L.C. (“Evercore”), Goldman Sachs & Co. LLC (“GS”) and each of the other Underwriters named... |
| 02 Sep 2025 |
8-K: Other Events
On September 2, 2025, Mineralys Therapeutics, Inc. (the “Company”) delivered written notice to BofA Securities, Inc. (“BofA”) and Evercore Group L.L.C. (“Evercore”), that it was suspending its use of and terminating the prospectus supple... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – |
| 17 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria |
| 22 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 22, 2025, Mineralys Therapeutics, Inc. (the Company) held its 2025 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown: |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – |
| 31 Mar 2025 |
8-K: Regulation FD Disclosure; Other Events
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) |
| 12 Mar 2025 |
8-K: Other Events
Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Evercore Group L.L.C. (“Evercore”), Goldman Sachs & Co. LLC (“GS”) and each of the other Underwriters named... |
Loading...